

Form PTO-1449 (modified)

Atty. Docket No.
VBLT:003USSerial No.
09/981,682

List of Patents and Publications for Applicant's

Applicant
Barney Scott Graham *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 16, 2001Group:
1646U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SCD	C5	Bandres <i>et al.</i> , "Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation," <i>J. Virology</i> , 72(3):2500-2504, 1998.
	C6	Choe <i>et al.</i> , "The β -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates," <i>Cell</i> , 85:1135-1148, 1996.
	C7	Del Villar <i>et al.</i> , "C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs," <i>Biochem. Soc. Trans.</i> , 24:709-713, 1996.
	C8	Doranz <i>et al.</i> , "A dual-tropic primary HIV-1 isolate that uses fusin and the β -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors," <i>Cell</i> , 85:1149-1158, 1996.
	C9	Endo <i>et al.</i> , "ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterologenesis produced by <i>Penicillium citrinum</i> ," <i>J. Antibiot.</i> , 12:1346-1348, 1976.
	C10	Endres <i>et al.</i> , "CD4-independent infection by HIV-2 is mediated by fusion/CXCR4," <i>Cell</i> , 87:745-756, 1996.
	C11	Fisher <i>et al.</i> , "Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge," <i>J. Infect. Dis.</i> 180:708-713, 1999.
	C12	Fukada <i>et al.</i> , "Farnesylated γ -subunit of photoreceptor G protein indispensable for GTP-binding," <i>Nature</i> , 346(6285):658-660, 1990.
	C13	Gong <i>et al.</i> , "Role of guanine nucleotide-binding-proteins--ras-family or trimeric proteins or both--in Ca^{2+} sensitization of smooth muscle," <i>Proc. Nat'l Acad. Sci. USA</i> , 93:1340-1345, 1996.
	C14	Gong <i>et al.</i> , "Translocation of rhoA associated with Ca^{2+} sensitization of smooth muscle," <i>J. Biol. Chem.</i> , 272:10704-10709, 1997.
	C15	Graham <i>et al.</i> , "Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with RSV-specific immune serum," <i>Pediatr. Res.</i> , 34(2):167-172, 1993.
	C16	Graham <i>et al.</i> , "Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin," <i>J. Infect. Dis.</i> , 171:1468-1474, 1995.
SCG	C17	Gruber <i>et al.</i> , "Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat," <i>Pediatr. Res.</i> , 21(3):270-274, 1987.

25093850.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED
JUN 18 2002
TECH CENTER 1600/2900

BEST AVAILABLE COPY

Form PTO-1449 (modified)

Atty. Docket No.
VBLT:003USSerial No.
09/981,682

List of Patents and Publications for Applicant's

Applicant
Barney Scott Graham *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 16, 2001Group:
1646U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
590	A1	5,141,851	8/25/92	Brown <i>et al.</i>	435	15	11/20/90
	A2	5,470,832	11/28/95	Gibbs <i>et al.</i>	514	18	1/31/94
	A3	5,756,528	5/26/98	Anthony <i>et al.</i>	514	399	5/23/96
	A4	5,773,455	6/30/98	Dong <i>et al.</i>	514	365	6/28/96
	A5	5,817,678	10/6/98	Kim <i>et al.</i>	514	326	11/15/96
	A6	5,830,868	11/3/98	Bolton <i>et al.</i>	514	18	6/27/96
599	A7	5,834,434	11/10/98	Sebti <i>et al.</i>	514	19	5/30/95

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
590	C1	Adamson <i>et al.</i> , "Post-translational modifications of p21 ^{tho} proteins," <i>J. Biol. Chem.</i> , 272(28): 20033-20038, 1992.
	C2	Alberts <i>et al.</i> , "Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent," <i>Proc. Nat'l Acad. Sci. USA</i> , 77(7): 3957-3961, 1980.
	C3	Alberts, "HMG-CoA reductase inhibitors - the development," <i>In: Atherosclerosis Reviews</i> , Stokes and Mancini (eds.), New York Raven Press, 18:123-131, 1988.
599	C4	Alkhatib <i>et al.</i> , "CC CKR5: a RANTES, MIP-1 α , MIP-1 β receptor as a fusion cofactor for macrophage-tropic HIV-1," <i>Science</i> , 272:1955-1958, 1996.

25093850.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

VBLT:003US

09/981,682

List of Patents and Publications for Applicant's

Applicant

Barney Scott Graham *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

October 16, 2001

1646

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>SAD</i>	C18	Higgins and Casey, "The role of prenylation in G-protein assembly and function," <i>Cell. Sig.</i> , 8(6):433-437, 1996.
	C19	Hirata <i>et al.</i> , "Involvement of Rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction," <i>J. Biol. Chem.</i> , 267: 8719-8722, 1992.
	C20	Koch <i>et al.</i> , "Role of Rho protein in lovastatin-induced breakdown of actin cytoskeleton," <i>J. Pharm. Exper. Ther.</i> , 283(2):901-909, 1997.
	C21	Kranenburg <i>et al.</i> , "Dissociation of LPA-induced cytoskeletal contraction from stress fiber formation by differential localization of RhoA," <i>J. Cell Sci.</i> , 110:2417-2427, 1997.
	C22	Lai <i>et al.</i> , "The γ subunit of transducin is farnesylated," <i>Proc. Natl. Acad. Sci., USA</i> , 87:7673-7677, 1990.
	C23	Maltese <i>et al.</i> , "Post-translational modification of low molecular mass GTP-binding proteins by isoprenoid," <i>J. Biol. Chem.</i> , 265(4):2148-2155, 1990.
	C24	Maziere <i>et al.</i> , "Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium," <i>Biomed & Pharmacother.</i> , 48:63-67, 1994.
	C25	Moore <i>et al.</i> , "Sequence dependence of protein isoprenylation," <i>J. Biol. Chem.</i> , 266(22):14603-14610, 1991.
	C26	Narumiya, "The small GTPase Rho: cellular functions and signal transduction," <i>J. Biochem.</i> , 120:215-228, 1996.
	C27	Nguyen and Hildreth, "Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts," <i>J. Virol.</i> , 74(7):3264-3272, 2000.
	C28	Overmeyer <i>et al.</i> , "Membrane targeting via protein prenylation," <i>Meth. Mol. Biol.</i> , 88:249-263, 1998.
	C29	Park and Galper, "3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase," <i>Proc. Nat'l Acad. Sci. USA</i> , 96:11525-11530, 1999.
	C30	Parker <i>et al.</i> , "Plasma mevalonate as a measure of cholesterol synthesis in man," <i>J. Clin. Invest.</i> , 75:795-804, 1984.
<i>SAD</i>	C31	Pastey <i>et al.</i> , "A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3," <i>Nat. Med.</i> , 6(1):35-40, 2000.

25093850.1

EXAMINER:

DATE CONSIDERED:

3/31/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

VBLT:003US

Serial No.

09/981,682

List of Patents and Publications for Applicant's

Applicant

Barney Scott Graham *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 16, 2001

Group:

1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
599	C32	Pastey <i>et al.</i> , "RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation," <i>J. Virol.</i> , 73(9):7262-7270, 1999.
	C33	Reiss <i>et al.</i> , "Sequence requirement for peptide recognition by rat brain p21 ^{ras} protein farnesyltransferase," <i>Proc. Natl. Acad. Sci. USA</i> , 88:732-736, 1991.
	C34	Ridley and Hall, "The small GTP binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors," <i>Cell</i> , 70:389-399, 1992.
	C35	Saito, "Analysis of the cellular functions of the small GTP-binding protein rho p21 with Clostridium botulinum C3 exoenzyme," <i>Pharmacol. Japonica / Nippon Yakurigaku Zasshi</i> , 109:13-17, 1997, Article in Japanese, Abstract included.
	C36	Scheiffele <i>et al.</i> , "Influenza viruses select ordered lipid domains during budding from the plasma membrane," <i>J. Biol. Chem.</i> , 274(4):2038-2044, 1999.
	C37	Sekine <i>et al.</i> , "Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase," <i>J. Biol. Chem.</i> , 264(15):8602-8605, 1989.
	C38	Stein <i>et al.</i> , "Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years," <i>Lancet</i> , 354:541-545, 1999.
	C39	Takai <i>et al.</i> , "Rho as a regulator of the cytoskeleton," <i>Trends Biochem. Sci.</i> , 20:227-231, 1995.
	C40	Treanor and Falsey, "Respiratory viral infections in the elderly," <i>Antiviral Res.</i> , 44:79-102, 1999.
	C41	Trueblood <i>et al.</i> , "Genetic evidence for in vivo cross-specificity of the CaaX-Box protein prenyltransferases farnesyltransferase and Geranylgeranyltransferase-I in <i>Saccharomyces cerevisiae</i> ," <i>Mol. and Cell. Biology</i> , 13(7):4260-4275, 1993.
	C42	Whyte <i>et al.</i> , "K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors," <i>J. Biol. Chem.</i> , 272(22):14459-14464, 1997.
	C43	Wyde <i>et al.</i> , "Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice." <i>Antiviral Res.</i> 7:211-220, 1987.
599	C44	Zhang <i>et al.</i> , "Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins," <i>J. Virol.</i> , 74(10):4634-4644, 2000.

25093850.1

EXAMINER:

DATE CONSIDERED:

3/31/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED
JUN 18 2002
TECH CENTER 1600/2900

BEST AVAILABLE COPY